98%
921
2 minutes
20
Adenosine-to-inosine RNA editing is an essential post-transcriptional modification catalyzed by adenosine deaminase acting on RNA (ADAR)1 and ADAR2 in mammals. For numerous sites in coding sequences (CDS) and microRNAs, editing is highly conserved and has significant biological consequences, for example, by altering amino acid residues and target recognition. However, no comprehensive and quantitative studies have been undertaken to determine how specific ADARs contribute to conserved sites in vivo. Here, we amplified each RNA region with editing site(s) separately and combined these for deep sequencing. Then, we compared the editing ratios of all sites that were conserved in CDS and microRNAs in the cerebral cortex and spleen of wild-type mice, mice expressing inactive ADAR1 (Adar1 KI) and (Adar2 KO) mice. We found that most of the sites showed a preference for one ADAR. In contrast, some sites, such as miR-3099-3p, showed no ADAR preference. In addition, we found that the editing ratio for several sites, such as DACT3 R/G, was up-regulated in either Adar mutant mouse strain, whereas a coordinated interplay between ADAR1 and ADAR2 was required for the efficient editing of specific sites, such as the 5-HTR B site. We further created double mutant Adar1 KI Adar2 KO mice and observed viable and fertile animals with the complete absence of editing, demonstrating that ADAR1 and ADAR2 are the sole enzymes responsible for all editing sites in vivo. Collectively, these findings indicate that editing is regulated in a site-specific manner by the different interplay between ADAR1 and ADAR2.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075269 | PMC |
http://dx.doi.org/10.1261/rna.072728.119 | DOI Listing |
Front Immunol
August 2025
Department of Laboratory Medicine, The Second Hospital of Jilin University, Changchun, China.
RNA is a fundamental biological macromolecule that undergoes several post-transcriptional modifications, including adenosine to inosine (A-to-I) editing by adenosine deaminases acting on RNA (ADARs). These essential enzymes catalyze the conversion of A-to-I in double-stranded RNA (dsRNA) molecules, influencing RNA stability, splicing, and translation, all of which impact various cellular functions. More recently, RNA editing has emerged as a pivotal mechanism in cancer biology, where ADARs, primarily ADAR1 and ADAR2, exert context-dependent roles as either oncogenic drivers or tumor suppressors.
View Article and Find Full Text PDFAnnu Rev Cell Dev Biol
July 2025
1Central European Institute for Technology, Masaryk University, Brno, Czechia; email:
The RNA editing enzyme adenosine deaminase acting on RNA 1 (ADAR1) has recently emerged from relative obscurity to be recognized as a key player in a variety of inflammatory diseases, including cancer. This growing recognition has generated interest in developing ADAR1 inhibitors; however, several fundamental questions about the enzyme need to be answered before ADAR1-based therapies can be successful. In this review, we summarize the current understanding of ADAR1, including its protein structure, RNA substrates, and roles in both innate and adaptive immunity.
View Article and Find Full Text PDFLab Invest
May 2025
Department of Human Pathology of Adults and Developmental Age "Gaetano Barresi", Division of Pathology, University of Messina, Messina, Italy. Electronic address:
In this retrospective observational multicenter study, we identified tumors and immune markers that are related to each other, which could help in selecting patients with bladder primary urothelial carcinoma in situ (CIS) who responded better to Bacillus Calmette-Guérin (BCG) therapy. Seventy-three patients with primary bladder CIS who were homogeneously treated with BCG were studied. Tumor-infiltrating lymphocytes (TILs) measured as CD4/CD8 ratio, androgen receptor (AR), adenosine deaminase acting on RNA 1 (ADAR1), adenosine deaminase acting on RNA 2 (ADAR2), and programmed death ligand 1 (PD-L1) expression were analyzed using immunohistochemistry, whereas miR-200a-3p and INF-γ were correlated with clinicopathological features and recurrence-free survival.
View Article and Find Full Text PDFMethods Enzymol
January 2025
St.Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia; Department of Medicine, St. Vincent's Hospital, Melbourne Medical School, University of Melbourne, Fitzroy, Victoria, Australia; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton
Adenosine-to-inosine (A-to-I) editing, is a highly prevalent posttranscriptional modification of RNA, mediated by the adenosine deaminases acting on RNA (ADAR) proteins. Mammalian transcriptomes contain tens of thousands to millions of A-to-I editing events. Mutations in ADAR can result in rare autoinflammatory disorders such as Aicardi-Goutières syndrome (AGS) through to irreversible conditions such as motor neuron disease, amyotrophic lateral sclerosis (ALS).
View Article and Find Full Text PDFGenes (Basel)
January 2025
Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
In the field of RNA therapy, innovative approaches based on adenosine deaminases acting on RNA (ADAR)-mediated site-directed RNA editing (SDRE) have been established, providing an exciting opportunity for RNA therapeutics. ADAR1 and ADAR2 enzymes are accountable for the predominant form of RNA editing in humans, which involves the hydrolytic deamination of adenosine (A) to inosine (I). This inosine is subsequently interpreted as guanosine (G) by the translational and splicing machinery because of their structural similarity.
View Article and Find Full Text PDF